Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026

Pasithea Therapeutics Corp. (KTTA) — -- Prolonged Stable Disease: PAS-004 achieved prolonged stable disease in a heavily pre-treated population, with four patients on PAS-004 for more than 300 days, including two who continue on once daily PAS-004 for over 500 days despite recurrent, metastatic melanoma carrying the BRAF V600E mutation and prior progression on targeted combination therapy with dabrafenib and trametinib. -- Long-Term Tolerability: Overall, the safety profile of PAS-004 in the heavily pre-treated advanced cancer popu

Source: GlobeNewswire — read the full announcement there.

See our Pasithea Therapeutics company profile for background, links, and more Pasithea Therapeutics news.